Proislet Peptide Stability via Terminal Modifications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diabetes, particularly type 1 and type 2, rely heavily on insulin administration, which does not fully manage glucose fluctuations and lacks a mechanism to regenerate insulin-producing pancreatic islets, leading to ongoing glucose metabolism issues and the need for innovative treatments that stimulate islet cell regeneration.
Innovation Solution
Development of Optimized proislet peptides, such as HIP variants modified with N-terminal acetyl and C-terminal amide groups, which enhance stability and bioavailability, allowing for effective administration to stimulate pancreatic islet neogenesis and improve glycemic control, potentially reducing the need for insulin and addressing impaired pancreatic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If proislet peptides are administered to stimulate pancreatic islet regeneration, then islet cell regeneration is promoted, but the peptides are rapidly degraded by serum proteases reducing bioavailability
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of proislet peptides through N-terminal acetylation and C-terminal amidation. These chemical modifications change the peptide's resistance parameter to protease cleavage, thereby extending its half-life in serum from minutes to hours while preserving its ability to stimulate islet cell regeneration.
Solution Approach 2:
The patent creates composite peptide structures by combining modified proislet peptide sequences with protective chemical groups at both termini. This composite approach integrates the bioactive peptide core with stabilizing chemical moieties, resulting in a molecule that resists proteolytic degradation while maintaining biological activity.
2Quantity of substance
If higher dosages of proislet peptides are administered to overcome rapid degradation, then bioavailability may be maintained, but treatment complexity and cost increase
Solution Approach 1:
By changing the chemical stability parameters of the peptide through terminal modifications, the patent enables effective dosing at lower concentrations. The modified peptides maintain adequate bioavailability at reduced dosages compared to unmodified peptides, simplifying treatment regimens and reducing overall peptide requirements.
3Stability of the object's composition
If N-terminal acetyl and C-terminal amide groups are added to block protease cleavage, then peptide stability in serum increases, but manufacturing complexity increases
Solution Approach 1:
The patent implements parameter changes by introducing terminal acetyl and amide groups during peptide synthesis. These modifications are incorporated into the synthesis protocol using standard chemical methods, achieving enhanced stability while maintaining compatibility with existing manufacturing processes.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof.